Results 101 to 110 of about 5,421 (159)

Zosurabalpin and the Revival of Pathogen-Specific Antibiotics: Targeting Lipopolysaccharide Transport in Carbapenem-Resistant Acinetobacter baumannii

Drugs and Drug Candidates
Carbapenem-resistant Acinetobacter baumannii (CRAB) is classified by the World Health Organization among the critical-priority pathogens, reflecting high mortality, near-ubiquitous nosocomial spread, and a depleted therapeutic pipeline.
Andrea Marino, Stefano Stracquadanio
doaj   +1 more source

What do We Know so Far about Ges Carbapenemases, and What Threat do They Pose?

Postępy Mikrobiologii
Carbapenemases, classified as bacterial enzymes, have the ability to hydrolyze carbapenems – important broad-spectrum antibiotics. This work attempts to summarize the information on the diversity of Guiana Extended-Spectrum (GES) subgroup of ...
Rutkowski Kamil, Osnytskyy Anton, Ślifierska Magdalena, Jarząbek Paulina, Bielec Filip, Pastuszak-Lewandoska Dorota, Brauncajs Małgorzata   +6 more
doaj   +1 more source

β-Lactam/β-Lactamase Inhibitor Combination Antibiotics Under Development

Pathogens
Antimicrobial resistance remains a public health problem of global concern with a great health and financial burden. Its recognition as a threat by political leadership has boosted the research and development of new antibiotics and particularly novel ...
Angeliki Katsarou, Panagiotis Stathopoulos, Iva D. Tzvetanova, Christina-Maria Asimotou, Matthew E. Falagas   +4 more
doaj   +1 more source

In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals

The activity of a novel β-lactamase inhibitor combination, sulbactam-durlobactam (SUL-DUR), was tested against 87 colistin-resistant and/or cefiderocol-non-susceptible carbapenem-resistant Acinetobacter baumannii clinical isolates collected from U.S ...
Cober, Eric, Hill, Carol, van Duin, David, Herc, Erica S, Bonomo, Robert A, Greenwood-Quaintance, Kerryl E, Chambers, Henry F, Arias, Cesar A, Fowler, Erin L, Baum, Keri, Doi, Yohei, Fowler, Vance G, Patel, Robin, McElheny, Christi L, Iovleva, Alina   +14 more
core   +1 more source

Successful Treatment of Carbapenem-Resistant <i>Acinetobacter baumannii</i> Infection with Sulbactam-Durlobactam: A Two-Case Report. [PDF]

Infect Drug Resist
Liu F, Wang DW.
europepmc   +1 more source

Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol : which are the best present and future therapeutic alternatives ?

Purpose: To evaluate the different present and future therapeutic β-lactam/β-lactamase inhibitor (BL/BLI) alternatives, namely aztreonam-avibactam, imipenem-relebactam, meropenem-vaborbactam, cefepime-zidebactam, cefepime-taniborbactam, meropenem ...
Le Terrier, Christophe, Freire, Samanta, Nordmann, Patrice, Poirel, Laurent   +3 more
core   +1 more source

Sulbactam for carbapenem-resistant Acinetobacter baumannii infections: a literature review

Carbapenem-resistant Acinetobacter baumannii (CRAB) is characterized as a critical priority pathogen with restricted therapeutic options. To date, the most effective antimicrobial treatment against this difficult-to-treat bacterial strain has not been ...
Agouridis, Aris P, Alon-Ellenbogen, Danny, Mazonakis, Nikolaos, Ishak, Angela, Spernovasilis, Nikolaos, Tsioutis, Constantinos   +5 more
core   +1 more source

Sulbactam-Durlobactam for Carbapenem-resistant <i>Acinetobacter baumannii</i> in India: Does Local Molecular Epidemiology Support Current Guideline Recommendations? [PDF]

Indian J Crit Care Med
Mukkelli VG, Gupta R.
europepmc   +1 more source

In vitro activity of cefoperazone and cefoperazone-sulbactam against carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa

, 2018
Chih-Cheng Lai,1 Chi-Chung Chen,2,3 Ying-Chen Lu,3 Yin-Ching Chuang,2,4 Hung-Jen Tang5,6 1Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying, Tainan, Taiwan; 2Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan ...
Tang HJ, Lu YC, Chen CC, Lai CC, Chuang YC   +4 more
core  

Critical Care Management of Pan-Resistant Acinetobacter Osteomyelitis Requiring Novel Antibiotic Therapy

A 65-year-old male with diabetes and chronic left heel osteomyelitis developed sepsis from pan-resistant Acinetobacter baumannii requiring emergent free flap surgery and initiation of sulbactam-durlobactam (Xacduro), a novel, rarely used antibiotic.
Navaratana, Nidhi, Soto, Roy, Thrasher, Patrick D, Shakibai, Nasim   +3 more
core   +1 more source